https://www.opko.com/ https://www.opko.com/therapies https://www.opko.com/therapies/human-growth-hormone-franchise https://www.opko.com/therapies/rayaldee https://www.opko.com/research/overview https://www.opko.com/research/pipeline https://www.opko.com/research/publications https://www.opko.com/research/scientific-presentations https://www.opko.com/diagnostics https://www.opko.com/company https://www.opko.com/company/leadership https://www.opko.com/company/locations https://www.opko.com/partnerships https://www.opko.com/investors https://www.opko.com/investors/news-events https://www.opko.com/investors/news-events/press-releases https://www.opko.com/investors/news-events/ir-calendar https://www.opko.com/investors/news-events/email-alerts https://www.opko.com/investors/presentations https://www.opko.com/investors/company-information https://www.opko.com/investors/company-information/proxy-materials https://www.opko.com/investors/company-information/contacts https://www.opko.com/investors/company-information/faq https://www.opko.com/investors/financial-information https://www.opko.com/investors/financial-information/financial-results https://www.opko.com/investors/financial-information/income-statement https://www.opko.com/investors/financial-information/balance-sheet https://www.opko.com/investors/financial-information/cash-flow https://www.opko.com/investors/stock-data/quote https://www.opko.com/investors/stock-data/charts https://www.opko.com/investors/stock-data/historical-data https://www.opko.com/investors/sec-filings https://www.opko.com/investors/sec-filings/all-sec-filings https://www.opko.com/investors/sec-filings/annual-reports https://www.opko.com/investors/sec-filings/quarterly-reports https://www.opko.com/investors/sec-filings/section-16-filings https://www.opko.com/investors/sec-filings/form-8937 https://www.opko.com/investors/corporate-governance https://www.opko.com/investors/corporate-governance/board-committees https://www.opko.com/investors/corporate-governance/governance-documents https://www.opko.com/investors/news-events/press-releases/detail/539/opko-health-to-participate-in-the-jefferies-biotech-on-the-beach-summit https://www.opko.com/investors/news-events/press-releases/detail/538/opko-health-reports-fourth-quarter-2025-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/537/opko-health-to-report-fourth-quarter-2025-financial-results-on-february-26 https://www.opko.com/investors/news-events/press-releases/detail/536/opko-health-and-entera-bio-expand-partnership-to-advance-first-in-class-oral-long-acting-pth-tablet-for-patients-with-hypoparathyroidism https://www.opko.com/investors/news-events/press-releases/detail/535/opko-health-to-participate-in-the-44th-annual-j-p-morgan-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/534/opko-health-to-participate-in-the-piper-sandler-37th-annual-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/533/opko-health-reports-third-quarter-2025-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/532/opko-healths-modex-therapeutics-enters-into-research-collaboration-with-regeneron-to-develop-multispecific-antibodies-for-select-therapeutic-indications https://www.opko.com/investors/news-events/press-releases/detail/531/opko-healths-modex-therapeutics-begins-clinical-trial-of-mdx2004-for-the-treatment-of-advanced-cancers https://www.opko.com/investors/news-events/press-releases/detail/530/opko-health-to-report-third-quarter-2025-financial-results-on-october-29 https://www.opko.com/investors/news-events/press-releases/detail/529/labcorp-completes-acquisition-of-select-assets-of-bioreference-healths-innovative-oncology-and-related-clinical-testing-services-businesses https://www.opko.com/investors/news-events/press-releases/detail/528/opko-health-reports-second-quarter-2025-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/527/opko-health-to-report-second-quarter-2025-financial-results-on-july-31 https://www.opko.com/investors/news-events/press-releases/detail/526/opko-health-and-entera-bio-announce-abstract-on-pkpd-of-oral-glp-2-tablet-for-the-treatment-of-short-bowel-syndrome-selected-for-2025-espen-congress https://www.opko.com/investors/news-events/press-releases/detail/525/opko-health-to-participate-in-the-3rd-annual-piper-sandler-virtual-obesity-symposium https://www.opko.com/investors/news-events/press-releases/detail/524/opko-health-and-entera-bio-abstract-for-first-in-class-dual-glp-1glucagon-tablet-candidate-for-patients-with-obesity-and-metabolic-disorders-selected-for-presentation-at-the-endo-2025-annual-meeting https://www.opko.com/investors/news-events/press-releases/detail/523/opko-healths-modex-therapeutics-announces-formation-of-scientific-advisory-board-with-leaders-at-the-forefront-of-immunology-and-oncology-drug-development https://www.opko.com/investors/news-events/press-releases/detail/522/opko-health-to-participate-in-two-upcoming-investor-conferences https://www.opko.com/investors/news-events/press-releases/detail/521/opko-health-reports-first-quarter-2025-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/520/opko-health-to-report-first-quarter-2025-financial-results-on-april-30-2025 https://www.opko.com/investors/news-events/press-releases/detail/519/opko-health-announces-100-million-increase-to-its-existing-share-repurchase-program https://www.opko.com/investors/news-events/press-releases/detail/517/opko-health-and-entera-bio-enter-into-collaboration-agreement-to-advance-oral-glp-1glucagon-tablet-candidate-into-the-clinic-to-treat-obesity-and-metabolic-disorders https://www.opko.com/investors/news-events/press-releases/detail/516/labcorp-announces-acquisition-of-select-assets-of-bioreference-healths-innovative-oncology-and-related-clinical-testing-services-businesses https://www.opko.com/investors/news-events/press-releases/detail/515/opko-health-reports-fourth-quarter-2024-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/514/opko-health-to-report-fourth-quarter-2024-financial-results-on-february-27-2025 https://www.opko.com/investors/news-events/press-releases/detail/513/opko-health-to-present-at-the-43rd-annual-j-p-morgan-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/512/opko-healths-modex-therapeutics-announces-epstein-barr-virus-vaccine-candidate-enters-phase-i-clinical-study-in-collaboration-with-merck https://www.opko.com/investors/news-events/press-releases/detail/511/opko-health-to-participate-in-the-piper-sandler-36th-annual-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/510/opko-health-reports-third-quarter-2024-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/509/opko-health-to-report-third-quarter-2024-financial-results-on-november-7-2024 https://www.opko.com/investors/news-events/press-releases/detail/508/modex-therapeutics-secures-35-million-barda-supplement-to-develop-covid-multispecific-antibodies-and-16-million-to-initiate-influenza-program https://www.opko.com/investors/news-events/press-releases/detail/507/entera-bio-and-opko-health-provide-update-on-pkpd-results-of-oral-oxyntomodulin-glp-1glucagon-peptide-tablet-candidate-for-obesity-and-metabolic-disorders https://www.opko.com/investors/news-events/press-releases/detail/506/opko-healths-modex-therapeutics-appoints-dr-giovanni-abbadessa-as-chief-medical-officer-as-pipeline-advances-into-clinical-development https://www.opko.com/investors/news-events/press-releases/detail/505/labcorp-completes-acquisition-of-select-assets-of-bioreference-healths-diagnostics-business-from-opko-health https://www.opko.com/investors/news-events/press-releases/detail/504/opko-health-reports-second-quarter-2024-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/503/opko-health-to-report-second-quarter-2024-financial-results-on-august-7-2024 https://www.opko.com/investors/news-events/press-releases/detail/502/opko-health-announces-100-million-share-repurchase-program https://www.opko.com/investors/news-events/press-releases/detail/501/opko-health-and-healthcare-royalty-enter-into-250-million-note-purchase-agreement-secured-by-ngenlas-profit-share-payments https://www.opko.com/investors/news-events/press-releases/detail/500/opko-health-to-participate-in-the-jefferies-global-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/499/opko-health-reports-first-quarter-2024-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/498/opko-health-to-report-first-quarter-2024-financial-results-on-may-7-2024 https://www.opko.com/investors/news-events/press-releases/detail/497/labcorp-announces-acquisition-of-select-assets-of-bioreference-healths-diagnostics-business https://www.opko.com/investors/news-events/press-releases/detail/496/aids-clinical-trial-group-presents-results-from-phase-1-study-of-modex-trispecific-antibody-for-the-treatment-and-prevention-of-hiv https://www.opko.com/investors/news-events/press-releases/detail/495/opko-health-reports-fourth-quarter-2023-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/494/opko-health-to-report-fourth-quarter-2023-financial-results-on-february-27-2024 https://www.opko.com/investors/news-events/press-releases/detail/493/opko-health-announces-closing-of-private-offering-of-230-million-convertible-senior-notes-due-2029-including-full-exercise-of-initial-purchasers-option-to-purchase-additional-notes https://www.opko.com/investors/news-events/press-releases/detail/492/opko-health-to-present-at-the-42nd-annual-j-p-morgan-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/491/opko-health-announces-pricing-of-private-offering-of-200-million-convertible-senior-notes-due-2029 https://www.opko.com/investors/news-events/press-releases/detail/490/opko-health-announces-private-offering-of-convertible-senior-notes-due-2029 https://www.opko.com/investors/news-events/press-releases/detail/489/opko-health-reports-third-quarter-2023-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/488/new-clinical-data-on-opko-healths-rayaldee-er-calcifediol-presented-at-kidney-week-2023 https://www.opko.com/investors/news-events/press-releases/detail/487/opko-health-to-report-third-quarter-2023-financial-results-on-november-6-2023 https://www.opko.com/investors/news-events/press-releases/detail/486/opko-health-to-present-new-clinical-data-on-rayaldee-er-calcifediol-at-kidney-week-2023 https://www.opko.com/investors/news-events/press-releases/detail/485/modex-therapeutics-secures-barda-contract-to-develop-novel-multispecific-antibodies-against-viral-infectious-disease-threats https://www.opko.com/investors/news-events/press-releases/detail/484/opko-health-reports-second-quarter-2023-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/483/opko-health-to-report-second-quarter-2023-financial-results-on-august-3-2023 https://www.opko.com/investors/news-events/press-releases/detail/482/fda-approves-pfizers-ngenla-a-long-acting-once-weekly-treatment-for-pediatric-growth-hormone-deficiency https://www.opko.com/investors/news-events/press-releases/detail/481/opko-health-reports-first-quarter-2023-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/480/opko-health-to-report-first-quarter-2023-financial-results-on-may-3-2023 https://www.opko.com/investors/news-events/press-releases/detail/479/opko-health-to-hold-virtual-rd-day-on-march-20-2023 https://www.opko.com/investors/news-events/press-releases/detail/478/opko-healths-modex-therapeutics-enters-into-exclusive-worldwide-license-and-collaboration-agreement-with-merck-to-develop-epstein-barr-virus-vaccine-candidate https://www.opko.com/investors/news-events/press-releases/detail/477/opko-health-reports-fourth-quarter-2022-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/476/opko-health-to-report-fourth-quarter-2022-financial-results-on-february-23-2023 https://www.opko.com/investors/news-events/press-releases/detail/475/opko-health-to-present-at-the-41st-annual-j-p-morgan-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/474/opko-health-reports-third-quarter-2022-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/473/opko-health-to-report-third-quarter-2022-financial-results-on-november-8-2022 https://www.opko.com/investors/news-events/press-releases/detail/472/opko-health-announces-leadership-changes-for-bioreference-laboratories https://www.opko.com/investors/news-events/press-releases/detail/471/opko-health-reports-2022-second-quarter-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/470/opko-health-to-report-second-quarter-2022-financial-results-on-august-4-2022 https://www.opko.com/investors/news-events/press-releases/detail/469/opko-health-to-present-at-the-2022-jefferies-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/468/opko-health-reports-2022-first-quarter-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/467/opko-health-acquires-modex-therapeutics-gains-proprietary-immunotherapy-technology-with-a-focus-on-oncology-and-infectious-diseases https://www.opko.com/investors/news-events/press-releases/detail/466/opko-health-to-report-first-quarter-2022-financial-results-on-may-9-2022 https://www.opko.com/investors/news-events/press-releases/detail/465/sema4-announces-the-completion-of-the-genedx-acquisition-and-a-streamlined-leadership-structure-to-accelerate-growth-of-its-diagnostic-and-clinical-data-platforms https://www.opko.com/investors/news-events/press-releases/detail/464/opko-health-reports-2021-fourth-quarter-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/463/opko-health-to-report-fourth-quarter-2021-financial-results-on-february-24-2022 https://www.opko.com/investors/news-events/press-releases/detail/462/pfizer-and-opkos-once-weekly-ngenlatm-somatrogon-injection-receives-marketing-authorization-in-european-union-for-treatment-of-pediatric-growth-hormone-deficiency https://www.opko.com/investors/news-events/press-releases/detail/461/rayaldee-launched-in-germany-by-opko-healths-licensee-vfmcrp https://www.opko.com/investors/news-events/press-releases/detail/460/pfizer-and-opko-provide-update-on-the-biologics-license-application-for-somatrogon-for-pediatric-growth-hormone-deficiency https://www.opko.com/investors/news-events/press-releases/detail/459/japans-mhlw-approves-pfizer-and-opkos-ngenla-somatrogon-a-new-long-acting-treatment-for-pediatric-growth-hormone-deficiency https://www.opko.com/investors/news-events/press-releases/detail/457/sema4-to-acquire-genedx-strengthening-its-market-leading-ai-driven-genomic-and-clinical-data-platform https://www.opko.com/investors/news-events/press-releases/detail/456/opko-health-to-participate-in-the-40th-annual-j-p-morgan-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/455/opko-health-announces-topline-results-from-phase-2-trial-evaluating-rayaldee-to-treat-symptomatic-covid-19-outpatients https://www.opko.com/investors/news-events/press-releases/detail/454/opko-health-receives-u-s-fda-approval-for-the-4kscore-test https://www.opko.com/investors/news-events/press-releases/detail/453/opko-health-announces-the-passing-of-director-dr-richard-lerner https://www.opko.com/investors/news-events/press-releases/detail/452/bioreference-laboratories-announces-readiness-for-covid-19-testing-if-the-omicron-covid-19-variant-emerges-in-the-u-s https://www.opko.com/investors/news-events/press-releases/detail/451/opko-health-announces-participation-in-piper-sandler-33rd-annual-virtual-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/450/opko-health-reports-2021-third-quarter-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/449/opko-health-to-report-third-quarter-2021-financial-results-on-october-28-2021 https://www.opko.com/investors/news-events/press-releases/detail/448/pfizer-and-opko-announce-extension-of-u-s-fda-review-of-biologics-license-application-of-somatrogon-for-pediatric-growth-hormone-deficiency https://www.opko.com/investors/news-events/press-releases/detail/447/leadermed-group-and-opko-health-form-joint-venture-to-develop-and-commercialize-oxyntomodulin-and-factor-viia-ctp-in-china-and-other-asian-territories https://www.opko.com/investors/news-events/press-releases/detail/446/opko-health-completes-enrollment-in-phase-2-trial-evaluating-rayaldee-as-a-treatment-for-symptomatic-covid-19-outpatients https://www.opko.com/investors/news-events/press-releases/detail/445/opko-health-to-participate-in-two-upcoming-investment-conferences https://www.opko.com/investors/news-events/press-releases/detail/444/rite-aid-in-partnership-with-the-u-s-department-of-health-and-human-services-bioreference-laboratories-and-new-york-state-announces-back-to-school-covid-19-testing-program https://www.opko.com/investors/news-events/press-releases/detail/443/bioreference-laboratories-acquires-u-s-ariosa-centralized-laboratory-prenatal-testing-business https://www.opko.com/investors/news-events/press-releases/detail/442/opko-health-reports-2021-second-quarter-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/441/opko-health-to-report-second-quarter-2021-financial-results-on-july-29-2021 https://www.opko.com/investors/news-events/press-releases/detail/440/opko-health-licenses-oligonucleotide-therapeutics-platform-to-camp4-therapeutics https://www.opko.com/investors/news-events/press-releases/detail/439/opko-health-to-present-at-the-ladenburg-thalmann-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/438/opko-health-appoints-katherine-stueland-as-president-and-ceo-of-genedx https://www.opko.com/investors/news-events/press-releases/detail/437/bioreference-laboratories-announces-first-covid-19-testing-program-for-cruise-industry https://www.opko.com/investors/news-events/press-releases/detail/436/opko-health-to-develop-and-commercialize-rayaldee-in-greater-china-with-nicoya-therapeutics https://www.opko.com/investors/news-events/press-releases/detail/435/opko-health-announces-sale-of-its-sterile-fill-and-finish-manufacturing-facility-in-ireland https://www.opko.com/investors/news-events/press-releases/detail/434/opko-health-to-participate-in-the-jefferies-virtual-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/433/opko-health-reports-transfer-of-licensed-rights-to-rayaldee-in-japan-to-vifor https://www.opko.com/investors/news-events/press-releases/detail/432/opko-health-enters-into-exchange-agreements-with-certain-4-5-convertible-senior-noteholders https://www.opko.com/investors/news-events/press-releases/detail/431/opko-health-reports-2021-first-quarter-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/430/major-league-soccer-renews-with-bioreference-laboratories-as-covid-19-testing-provider-for-second-year https://www.opko.com/investors/news-events/press-releases/detail/429/opko-health-to-report-first-quarter-2021-financial-results-on-april-28-2021 https://www.opko.com/investors/news-events/press-releases/detail/428/bioreference-laboratories-expands-its-major-league-sports-relationships-with-addition-of-major-league-baseball https://www.opko.com/investors/news-events/press-releases/detail/427/bioreference-laboratories-expands-covid-19-school-testing-program https://www.opko.com/investors/news-events/press-releases/detail/426/ema-accepts-marketing-application-for-somatrogon-to-treat-pediatric-patients-with-growth-hormone-deficiency https://www.opko.com/investors/news-events/press-releases/detail/425/new-york-state-partners-with-bioreference-laboratories-to-spearhead-the-ny-forward-covid-19-rapid-test-program-to-help-reopen-the-new-york-economy https://www.opko.com/investors/news-events/press-releases/detail/424/opko-health-reports-2020-fourth-quarter-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/423/opko-health-to-report-fourth-quarter-2020-financial-results-on-february-18-2021 https://www.opko.com/investors/news-events/press-releases/detail/422/new-drug-application-submitted-to-pmda-in-japan-for-somatrogon-to-treat-pediatric-patients-with-growth-hormone-deficiency https://www.opko.com/investors/news-events/press-releases/detail/421/opko-healths-genedx-adds-repeat-expansion-analysis-genetic-tests-for-diagnosis-of-spinocerebellar-ataxia-sca-friedreich-ataxia-and-other-common-forms-of-hereditary-ataxia https://www.opko.com/investors/news-events/press-releases/detail/420/opko-healths-bioreference-laboratories-team-up-with-the-national-basketball-association-and-national-hockey-league-to-provide-players-and-staff-with-covid-19-testing https://www.opko.com/investors/news-events/press-releases/detail/419/opko-healths-bioreference-laboratories-introduces-scarlet-health-an-in-home-diagnostic-service-to-expand-digital-health-access https://www.opko.com/investors/news-events/press-releases/detail/418/opko-health-to-present-at-the-39th-annual-j-p-morgan-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/417/us-fda-accepts-regulatory-submission-from-pfizer-and-opko-for-review-of-somatrogon-to-treat-pediatric-patients-with-growth-hormone-deficiency https://www.opko.com/investors/news-events/press-releases/detail/416/opko-healths-bioreference-laboratories-reports-results-of-the-largest-covid-19-public-school-testing-program-nationwide https://www.opko.com/investors/news-events/press-releases/detail/415/buffalo-bills-and-opko-healths-bioreference-laboratories-initiate-the-first-large-scale-mandatory-covid-19-fan-testing-program https://www.opko.com/investors/news-events/press-releases/detail/414/opko-health-appoints-dr-roger-medel-to-its-board-of-directors https://www.opko.com/investors/news-events/press-releases/detail/413/opko-health-to-participate-in-three-upcoming-investment-conferences https://www.opko.com/investors/news-events/press-releases/detail/412/opko-health-reports-2020-third-quarter-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/411/opko-healths-bioreference-laboratories-launches-multiplex-covid-19-and-influenza-ab-test https://www.opko.com/investors/news-events/press-releases/detail/410/opko-health-to-report-third-quarter-2020-financial-results-on-october-29-2020 https://www.opko.com/investors/news-events/press-releases/detail/409/opko-healths-bioreference-laboratories-launches-covid-19-testing-program-for-new-york-city-schools https://www.opko.com/investors/news-events/press-releases/detail/408/pfizer-announces-positive-phase-3-top-line-results-for-once-weekly-investigational-long-acting-human-growth-hormone-to-treat-children-with-growth-hormone-deficiency https://www.opko.com/investors/news-events/press-releases/detail/407/opko-health-initiates-clinical-trial-of-rayaldee-in-covid-19-patients https://www.opko.com/investors/news-events/press-releases/detail/406/opko-health-to-participate-in-two-september-investment-conferences https://www.opko.com/investors/news-events/press-releases/detail/405/opko-healths-bioreference-laboratories-announces-new-york-city-schools-covid-19-testing-program https://www.opko.com/investors/news-events/press-releases/detail/404/opko-healths-bioreference-laboratories-launches-best-in-class-next-generation-sequencing-ngs-assay https://www.opko.com/investors/news-events/press-releases/detail/403/opko-healths-genedx-enters-into-agreement-with-pediatrix-medical-group-to-offer-neonatal-genomic-services https://www.opko.com/investors/news-events/press-releases/detail/402/opko-health-to-participate-in-btig-virtual-biotechnology-conference https://www.opko.com/investors/news-events/press-releases/detail/401/opko-health-reports-2020-second-quarter-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/400/opko-health-to-report-second-quarter-2020-financial-results-on-july-30-2020 https://www.opko.com/investors/news-events/press-releases/detail/399/opko-healths-bioreference-laboratories-awarded-commercial-surge-capacity-testing-for-covid-19-emergency-response-contract-by-centers-for-disease-control-and-prevention-cdc https://www.opko.com/investors/news-events/press-releases/detail/398/opko-healths-bioreference-laboratories-to-provide-covid-19-testing-for-national-basketball-association-players-and-employees https://www.opko.com/investors/news-events/press-releases/detail/397/major-league-soccer-chooses-opko-healths-bioreference-laboratories-to-provide-covid-19-testing-for-players-and-employees https://www.opko.com/investors/news-events/press-releases/detail/396/opko-healths-bioreference-laboratories-reports-results-of-covid-19-testing-for-almost-one-quarter-of-a-million-nursing-home-and-live-in-facility-employees https://www.opko.com/investors/news-events/press-releases/detail/395/opko-health-announces-positive-top-line-results-of-phase-3-efficacy-and-safety-study-of-somatrogon-for-the-treatment-of-japanese-children-with-growth-hormone-deficiency https://www.opko.com/investors/news-events/press-releases/detail/394/fda-authorizes-opko-health-clinical-trial-evaluating-rayaldee-in-covid-19-patients https://www.opko.com/investors/news-events/press-releases/detail/393/opko-health-to-present-at-the-jefferies-virtual-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/392/opko-healths-bioreference-laboratories-launches-covid-19-employer-solution https://www.opko.com/investors/news-events/press-releases/detail/391/opko-healths-bioreference-laboratories-and-westchester-medical-center-health-network-enter-into-strategic-laboratory-collaboration-to-deliver-operational-and-diagnostic-services https://www.opko.com/investors/news-events/press-releases/detail/390/opko-healths-bioreference-laboratories-launches-covid-19-antibody-screening-for-new-york-city-residents https://www.opko.com/investors/news-events/press-releases/detail/389/opko-health-reports-2020-first-quarter-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/388/opko-health-to-report-first-quarter-2020-financial-results-on-may-6-2020 https://www.opko.com/investors/news-events/press-releases/detail/387/opko-healths-bioreference-laboratories-in-partnership-with-new-york-state-initiates-testing-for-covid-19-antibodies https://www.opko.com/investors/news-events/press-releases/detail/386/somatrogon-phase-3-pediatric-trial-results-will-be-presented-on-june-8-at-endo-online-2020 https://www.opko.com/investors/news-events/press-releases/detail/385/opko-healths-bioreference-laboratories-partners-with-hospitals-nationwide-to-provide-prioritized-testing-to-inpatients-with-suspected-coronavirus-disease-2019-covid-19 https://www.opko.com/investors/news-events/press-releases/detail/384/opko-health-reports-interim-results-for-two-ongoing-rayaldee-studies https://www.opko.com/investors/news-events/press-releases/detail/383/opko-healths-bioreference-laboratories-and-city-of-miami-provide-testing-for-coronavirus-disease-2019-covid-19 https://www.opko.com/investors/news-events/press-releases/detail/382/opko-healths-bioreference-laboratories-and-city-of-detroit-provide-testing-for-coronavirus-disease-2019-covid-19 https://www.opko.com/investors/news-events/press-releases/detail/381/opko-healths-bioreference-laboratories-and-state-of-new-jersey-provide-testing-for-coronavirus-disease-2019-covid-19 https://www.opko.com/investors/news-events/press-releases/detail/380/opko-healths-bioreference-laboratories-and-nyc-health-hospitals-enter-into-laboratory-collaboration-to-provide-testing-for-coronavirus-disease-2019-covid-19 https://www.opko.com/investors/news-events/press-releases/detail/379/opkos-bioreference-laboratories-offers-testing-for-coronavirus-disease-2019-covid-19 https://www.opko.com/investors/news-events/press-releases/detail/378/opko-healths-bioreference-laboratories-to-introduce-coronavirus-disease-covid-19-test https://www.opko.com/investors/news-events/press-releases/detail/377/opko-health-reports-2019-fourth-quarter-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/376/opko-health-to-report-fourth-quarter-2019-financial-results-on-february-26-2020 https://www.opko.com/investors/news-events/press-releases/detail/375/opko-health-to-present-at-the-38th-annual-j-p-morgan-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/374/31st-annual-piper-jaffray-healthcare-conference-fireside-chat-updated-webcast-link https://www.opko.com/investors/news-events/press-releases/detail/373/opko-health-to-participate-in-the-31st-annual-piper-jaffray-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/372/novitas-issues-final-local-coverage-determination-for-the-4kscore-test https://www.opko.com/investors/news-events/press-releases/detail/371/opko-health-reports-2019-third-quarter-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/370/opko-health-to-report-third-quarter-2019-financial-results-on-november-5-2019 https://www.opko.com/investors/news-events/press-releases/detail/369/opko-health-inc-announces-pricing-of-its-offering-of-common-stock https://www.opko.com/investors/news-events/press-releases/detail/368/opko-health-inc-announces-proposed-offering-of-common-stock https://www.opko.com/investors/news-events/press-releases/detail/367/opko-and-pfizer-announce-positive-phase-3-top-line-results-for-somatrogon-an-investigational-long-acting-human-growth-hormone-to-treat-children-with-growth-hormone-deficiency https://www.opko.com/investors/news-events/press-releases/detail/366/opko-completes-pivotal-phase-3-study-for-somatrogon-hgh-ctp-an-investigational-long-acting-growth-hormone-being-studied-for-the-treatment-of-children-with-growth-hormone-deficiency https://www.opko.com/investors/news-events/press-releases/detail/365/opko-health-reports-2019-second-quarter-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/364/opko-health-to-report-second-quarter-2019-financial-results-on-august-7-2019 https://www.opko.com/investors/news-events/press-releases/detail/363/opko-healths-bioreference-laboratories-forms-a-strategic-collaboration-with-somos-to-improve-health-outcomes-of-underserved-new-yorkers https://www.opko.com/investors/news-events/press-releases/detail/362/novitas-issues-proposed-local-coverage-determination-for-the-4kscore-test https://www.opko.com/investors/news-events/press-releases/detail/361/opko-health-submits-de-novo-request-to-the-u-s-fda-for-the-4kscore-test https://www.opko.com/investors/news-events/press-releases/detail/360/opko-health-reports-2019-first-quarter-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/359/opko-health-to-report-first-quarter-2019-financial-results-on-may-7-2019 https://www.opko.com/investors/news-events/press-releases/detail/358/opko-reports-additional-oxyntomodulin-opk-88003-results-from-phase-2-diabetes-and-obesity-trial https://www.opko.com/investors/news-events/press-releases/detail/357/opko-announces-positive-topline-results-in-phase-2-diabetes-and-obesity-trial https://www.opko.com/investors/news-events/press-releases/detail/356/opko-health-reports-2018-fourth-quarter-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/355/opko-health-to-announce-fourth-quarter-2018-financial-results-on-february-27-2019 https://www.opko.com/investors/news-events/press-releases/detail/354/opko-health-inc-announces-the-pricing-of-its-offering-of-convertible-senior-notes https://www.opko.com/investors/news-events/press-releases/detail/353/opko-health-inc-announces-proposed-offering-of-convertible-senior-notes https://www.opko.com/investors/news-events/press-releases/detail/352/opko-health-receives-fda-approval-for-the-point-of-care-sangia-psa-test-with-the-claros-1-analyzer https://www.opko.com/investors/news-events/press-releases/detail/351/opko-provides-update-on-the-development-of-opk-88004-a-selective-androgen-receptor-modulator https://www.opko.com/investors/news-events/press-releases/detail/350/future-non-coverage-determination-for-4kscore-test-posted-by-novitas https://www.opko.com/investors/news-events/press-releases/detail/349/opko-health-appoints-jon-r-cohen-m-d-executive-chairman-of-bioreference-laboratories https://www.opko.com/investors/news-events/press-releases/detail/348/opko-health-and-opkos-ceo-and-chairman-dr-phillip-frost-announce-proposed-resolution-of-sec-action https://www.opko.com/investors/news-events/press-releases/detail/347/opko-health-reports-third-quarter-2018-financial-results https://www.opko.com/investors/news-events/press-releases/detail/346/bioreference-laboratories-named-as-preferred-laboratory-with-horizon-healthcare-services https://www.opko.com/investors/news-events/press-releases/detail/345/opko-health-to-announce-third-quarter-2018-financial-results-on-november-9-2018 https://www.opko.com/investors/news-events/press-releases/detail/344/opko-confirms-resumption-of-common-stock-trading-on-nasdaq https://www.opko.com/investors/news-events/press-releases/detail/343/opko-comments-on-continued-nasdaq-halt-of-trading-of-common-stock https://www.opko.com/investors/news-events/press-releases/detail/342/opko-comments-on-sec-complaint https://www.opko.com/investors/news-events/press-releases/detail/341/opko-initiates-rayaldee-phase-2-trial-in-dialysis-patients https://www.opko.com/investors/news-events/press-releases/detail/340/opko-healths-bioreference-laboratories-to-participate-in-the-national-cancer-institute-nci-match-molecular-analysis-for-therapy-choice-phase-ii-clinical-trial https://www.opko.com/investors/news-events/press-releases/detail/339/opko-health-reports-second-quarter-2018-financial-results https://www.opko.com/investors/news-events/press-releases/detail/338/opko-health-completes-enrollment-in-global-phase-3-study-of-somatrogon-hgh-ctp-in-growth-hormone-deficient-children https://www.opko.com/investors/news-events/press-releases/detail/337/opko-health-to-announce-second-quarter-2018-financial-results-on-august-7-2018 https://www.opko.com/investors/news-events/press-releases/detail/336/opko-partner-vifor-fresenius-receives-marketing-approval-for-rayaldee-in-canada https://www.opko.com/investors/news-events/press-releases/detail/335/genedx-announces-completion-of-100000-exome-sequences https://www.opko.com/investors/news-events/press-releases/detail/334/opko-health-completes-enrollment-in-phase-2b-study-of-opk88003-to-treat-type-2-diabetes-and-obesity https://www.opko.com/investors/news-events/press-releases/detail/333/opko-plans-to-address-draft-local-coverage-determination-published-by-novitas-solutions-for-4kscore-test https://www.opko.com/investors/news-events/press-releases/detail/332/opko-health-reports-first-quarter-2018-financial-results https://www.opko.com/investors/news-events/press-releases/detail/331/opko-health-to-announce-first-quarter-2018-financial-results-on-may-8-2018 https://www.opko.com/investors/news-events/press-releases/detail/330/opko-health-appoints-geoff-monk-general-manager-at-bioreference-laboratories https://www.opko.com/investors/news-events/press-releases/detail/329/opko-health-to-remain-on-the-tel-aviv-stock-exchange https://www.opko.com/investors/news-events/press-releases/detail/328/opko-health-enrolls-first-patient-in-phase-2b-study-of-opk88003-to-treat-type-2-diabetes https://www.opko.com/investors/news-events/press-releases/detail/327/opko-health-announces-landmark-study-showing-4kscore-test-is-strong-predictor-of-prostate-cancer-mortality-published-in-european-urology https://www.opko.com/investors/news-events/press-releases/detail/326/opko-health-reports-2017-fourth-quarter-business-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/325/opko-health-to-announce-fourth-quarter-and-year-end-2017-financial-results-on-march-1-2018 https://www.opko.com/investors/news-events/press-releases/detail/324/opko-health-announces-leadership-changes-at-bioreference-laboratories https://www.opko.com/investors/news-events/press-releases/detail/323/opkos-genedx-announces-research-collaboration-with-radboud-university-medical-center https://www.opko.com/investors/news-events/press-releases/detail/322/opko-health-enrolls-first-patient-in-phase-2b-study-of-opk88004-to-treat-benign-prostatic-hypertrophy https://www.opko.com/investors/news-events/press-releases/detail/321/opko-health-reports-2017-third-quarter-highlights-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/320/opko-health-submits-premarket-approval-application-with-fda-for-a-point-of-care-psa-test-with-the-claros-1-platform https://www.opko.com/investors/news-events/press-releases/detail/319/opko-health-to-announce-2017-third-quarter-financial-results-on-november-8-2017 https://www.opko.com/investors/news-events/press-releases/detail/318/opko-health-licensee-tesaro-announces-fda-approval-of-varubi-iv-for-delayed-nausea-and-vomiting-associated-with-chemotherapy https://www.opko.com/investors/news-events/press-releases/detail/317/opko-health-enters-into-exclusive-agreement-with-japan-tobacco-to-develop-and-commercialize-rayaldee-in-japan https://www.opko.com/investors/news-events/press-releases/detail/316/opkos-bioreference-laboratories-and-the-garage-announce-national-strategic-affiliation-to-enhance-value-based-care https://www.opko.com/investors/news-events/press-releases/detail/315/opkos-genedx-to-showcase-leadership-in-genetic-testing-at-the-national-society-of-genetic-counselors-and-the-american-society-of-human-genetics-annual-meetings https://www.opko.com/investors/news-events/press-releases/detail/314/opko-health-to-present-at-upcoming-september-conferences https://www.opko.com/investors/news-events/press-releases/detail/313/opko-health-reports-second-quarter-2017-business-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/312/opko-health-to-announce-2017-second-quarter-financial-results-on-august-8-2017 https://www.opko.com/investors/news-events/press-releases/detail/311/opko-health-announces-kdigo-clinical-practice-guideline-update-on-ckd-mbd https://www.opko.com/investors/news-events/press-releases/detail/310/opko-provides-update-to-topline-data-of-phase-3-clinical-study-of-hgh-ctp-in-growth-hormone-deficient-adults https://www.opko.com/investors/news-events/press-releases/detail/309/opkos-genedx-extends-relationship-with-university-of-california-health-for-genetic-and-molecular-testing https://www.opko.com/investors/news-events/press-releases/detail/308/opko-health-provides-commercial-update-for-rayaldee https://www.opko.com/investors/news-events/press-releases/detail/307/opko-healths-4kscore-test-highlighted-in-podium-presentation-at-112th-american-urological-association-annual-meeting https://www.opko.com/investors/news-events/press-releases/detail/306/opko-announces-multiple-presentations-at-the-112th-american-urological-association-annual-meeting https://www.opko.com/investors/news-events/press-releases/detail/304/opko-health-reports-2017-financial-and-operating-results https://www.opko.com/investors/news-events/press-releases/detail/303/opko-health-to-announce-2017-first-quarter-financial-results-on-may-9-2017 https://www.opko.com/investors/news-events/press-releases/detail/302/opko-receives-fda-orphan-drug-status-for-its-new-oligonucleotide-to-treat-genetic-neurological-disorder https://www.opko.com/investors/news-events/press-releases/detail/301/opko-healths-genedx-to-have-significant-presence-at-acmg-2017 https://www.opko.com/investors/news-events/press-releases/detail/300/opko-health-to-participate-in-the-barclays-global-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/299/opko-receives-eu-orphan-drug-status-for-its-new-oligonucleotide-to-treat-genetic-neurological-disorder https://www.opko.com/investors/news-events/press-releases/detail/298/opko-subsidiary-genpath-womens-health-announces-the-availability-of-claritest https://www.opko.com/investors/news-events/press-releases/detail/297/opko-health-appoints-dr-akhtar-ashfaq-as-renal-division-senior-vice-president-clinical-research-and-development https://www.opko.com/investors/news-events/press-releases/detail/296/opko-health-reports-2016-financial-and-operating-results https://www.opko.com/investors/news-events/press-releases/detail/295/opko-healths-genedx-announces-participation-in-illuminas-ihope-program-on-international-rare-disease-day https://www.opko.com/investors/news-events/press-releases/detail/294/opko-health-to-announce-2016-fourth-quarter-financial-results-on-march-1-2017 https://www.opko.com/investors/news-events/press-releases/detail/293/opko-health-to-participate-at-upcoming-healthcare-investment-conferences https://www.opko.com/investors/news-events/press-releases/detail/292/opko-spain-to-start-trial-of-once-a-year-intra-articular-injectable-for-osteoarthritis https://www.opko.com/investors/news-events/press-releases/detail/291/opko-health-promotes-thomas-nusbickel-to-renal-division-chief-commercial-officer https://www.opko.com/investors/news-events/press-releases/detail/290/opkos-genedx-announces-research-collaboration-with-the-wellcome-trust-sanger-institute https://www.opko.com/investors/news-events/press-releases/detail/289/opko-investee-zebra-biologics-announces-collaboration-with-abbvie-to-discover-new-antibody-therapeutics https://www.opko.com/investors/news-events/press-releases/detail/288/opko-announces-initiation-of-claros-1-clinical-trial-for-total-psa https://www.opko.com/investors/news-events/press-releases/detail/287/opko-health-to-present-at-the-j-p-morgan-35th-annual-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/286/opko-health-provides-update-on-hgh-ctp-clinical-programs https://www.opko.com/investors/news-events/press-releases/detail/285/opko-health-to-be-added-to-the-nasdaq-biotechnology-index https://www.opko.com/investors/news-events/press-releases/detail/284/opko-health-to-participate-at-three-investment-conferences-in-december https://www.opko.com/investors/news-events/press-releases/detail/283/opko-announces-u-s-launch-of-rayaldee https://www.opko.com/investors/news-events/press-releases/detail/282/opko-presents-data-on-rayaldee-at-asn-kidney-week-2016 https://www.opko.com/investors/news-events/press-releases/detail/281/opko-health-reports-third-quarter-financial-and-operating-results https://www.opko.com/investors/news-events/press-releases/detail/280/opko-to-announce-third-quarter-operating-and-financial-results-on-november-7-2016 https://www.opko.com/investors/news-events/press-releases/detail/279/opko-health-enters-companion-animal-health-market https://www.opko.com/investors/news-events/press-releases/detail/278/opko-health-appoints-dr-benjamin-solomon-as-managing-director-of-genedx https://www.opko.com/investors/news-events/press-releases/detail/277/opko-health-to-present-at-the-ladenburg-thalmann-2016-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/276/opko-health-appoints-jane-pine-wood-as-chief-legal-and-compliance-officer-of-bioreference-laboratories https://www.opko.com/investors/news-events/press-releases/detail/275/opko-to-present-long-acting-human-growth-hormone-hgh-ctp-phase-2-pediatric-growth-hormone-deficiency-data-at-the-55th-annual-meeting-of-the-european-society-for-paediatric-endocrinology https://www.opko.com/investors/news-events/press-releases/detail/274/opko-health-to-participate-in-upcoming-september-conferences https://www.opko.com/investors/news-events/press-releases/detail/273/opko-health-completes-acquisition-of-transition-therapeutics https://www.opko.com/investors/news-events/press-releases/detail/272/transition-therapeutics-shareholders-approve-acquisition-by-opko-health https://www.opko.com/investors/news-events/press-releases/detail/271/opko-health-responds-to-law-firm-notice-of-investigation https://www.opko.com/investors/news-events/press-releases/detail/270/opko-health-reports-improved-financial-and-operating-results https://www.opko.com/investors/news-events/press-releases/detail/269/opko-to-announce-second-quarter-operating-and-financial-results-on-august-8-2016 https://www.opko.com/investors/news-events/press-releases/detail/268/fda-approves-new-drug-application-for-rayaldee-to-treat-secondary-hyperparathyroidism-associated-with-vitamin-d-insufficiency-in-stage-3-4-chronic-kidney-disease https://www.opko.com/investors/news-events/press-releases/detail/267/opko-health-to-host-analyst-investor-day-in-new-york-city-on-june-15 https://www.opko.com/investors/news-events/press-releases/detail/266/opko-health-announces-move-to-nasdaq-stock-market https://www.opko.com/investors/news-events/press-releases/detail/265/opko-to-discuss-draft-coverage-determinations-for-4kscore-test-at-2016-jefferies-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/264/opko-health-to-present-at-the-2016-jefferies-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/263/opko-health-receives-proposeddraft-medicare-local-coverage-determination-for-4kscore-test https://www.opko.com/investors/news-events/press-releases/detail/262/opko-announces-appointment-of-douglass-laidlaw-as-vice-president-of-medical-affairs https://www.opko.com/investors/news-events/press-releases/detail/261/opko-announces-appointment-of-thomas-nusbickel-as-senior-vice-president-of-pharmaceutical-marketing-and-market-access https://www.opko.com/investors/news-events/press-releases/detail/260/opko-health-reports-first-quarter-financial-and-operating-results https://www.opko.com/investors/news-events/press-releases/detail/259/vifor-fresenius-medical-care-renal-pharma-and-opko-health-enter-into-agreement-for-opkos-rayaldee https://www.opko.com/investors/news-events/press-releases/detail/258/opko-to-announce-first-quarter-operating-and-financial-results-on-may-9-2016 https://www.opko.com/investors/news-events/press-releases/detail/257/opko-presents-additional-data-on-rayaldee-at-national-kidney-foundation-spring-clinical-meetings-2016 https://www.opko.com/investors/news-events/press-releases/detail/256/fda-accepts-resubmission-of-new-drug-application-for-rayaldee https://www.opko.com/investors/news-events/press-releases/detail/255/opko-announces-appointment-of-james-demarco-as-senior-vice-president-of-pharmaceutical-sales https://www.opko.com/investors/news-events/press-releases/detail/254/opko-presents-additional-data-on-rayaldee-at-endo-2016 https://www.opko.com/investors/news-events/press-releases/detail/253/opko-presents-additional-data-on-rayaldee-to-treat-secondary-hyperparathyroidism-in-chronic-kidney-disease https://www.opko.com/investors/news-events/press-releases/detail/252/opko-receives-complete-response-letter-from-fda-for-rayaldee-new-drug-application https://www.opko.com/investors/news-events/press-releases/detail/251/opko-health-announces-executive-appointment https://www.opko.com/investors/news-events/press-releases/detail/250/opko-to-present-18-24-month-clinical-data-on-its-long-acting-human-growth-hormone-hgh-ctp-from-open-label-extension-ole-phase-2-pediatric-growth-hormone-deficiency-clinical-study-in-oral-presentation-at-endo-2016 https://www.opko.com/investors/news-events/press-releases/detail/249/opko-health-announces-dosing-of-first-subject-in-phase-1-clinical-study-of-a-long-acting-oxyntomodulin-for-the-treatment-of-obesity-and-type-ii-diabetes https://www.opko.com/investors/news-events/press-releases/detail/248/opko-4kscore-recommended-in-2016-european-association-of-urology-prostate-cancer-guidelines https://www.opko.com/investors/news-events/press-releases/detail/247/opko-health-names-dr-gregory-henderson-president-of-bio-reference-laboratories https://www.opko.com/investors/news-events/press-releases/detail/246/opko-health-to-present-at-the-2016-barclays-global-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/245/opkos-genedx-presenting-on-a-number-of-topics-at-the-2016-acmg-annual-clinical-genetics-meeting https://www.opko.com/investors/news-events/press-releases/detail/244/opko-announces-financial-and-operating-results https://www.opko.com/investors/news-events/press-releases/detail/243/opkos-genedx-participating-in-the-molecular-medicine-tri-conference-2016-in-san-francisco https://www.opko.com/investors/news-events/press-releases/detail/242/opko-health-announces-dosing-of-first-patient-in-phase-2a-clinical-study-of-a-long-acting-factor-viia-for-the-treatment-of-hemophilia https://www.opko.com/investors/news-events/press-releases/detail/241/opko-to-announce-2015-fourth-quarter-and-full-year-financial-results-on-february-29-2016 https://www.opko.com/investors/news-events/press-releases/detail/240/opko-health-to-present-at-the-rbc-capital-markets-global-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/239/study-demonstrates-opkos-4kscore-test-reduces-unnecessary-prostate-biopsies-while-improving-risk-prediction-for-aggressive-prostate-cancer https://www.opko.com/investors/news-events/press-releases/detail/238/opkos-genedx-to-present-at-personalized-medicine-world-conference https://www.opko.com/investors/news-events/press-releases/detail/237/opko-health-to-present-at-the-j-p-morgan-34th-annual-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/236/conversion-right-extended-on-opko-3-0-convertible-senior-notes https://www.opko.com/investors/news-events/press-releases/detail/235/opkos-genedx-study-of-more-than-10000-individuals-tested-with-multigene-ngs-hereditary-cancer-panel-reveals-new-risks https://www.opko.com/investors/news-events/press-releases/detail/234/opkos-genedx-study-demonstrates-whole-exome-sequencing-usefulness-in-diagnosing-rare-disorders https://www.opko.com/investors/news-events/press-releases/detail/233/opko-health-to-present-at-the-oppenheimer-26th-annual-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/232/opko-health-to-present-at-the-jefferies-autumn-2015-global-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/231/opko-licensee-tesaro-announces-the-launch-of-varubitm-rolapitant-in-the-united-states https://www.opko.com/investors/news-events/press-releases/detail/230/opko-4kscore-test-receives-category-i-cpt-code-approval https://www.opko.com/investors/news-events/press-releases/detail/229/opko-announces-third-quarter-financial-and-operating-results https://www.opko.com/investors/news-events/press-releases/detail/228/opko-health-refinances-bio-reference-laboratories-credit-facility https://www.opko.com/investors/news-events/press-releases/detail/227/opko-to-announce-third-quarter-operating-and-financial-results-on-november-9-2015 https://www.opko.com/investors/news-events/press-releases/detail/226/additional-phase-3-data-supporting-opkos-rayaldee-as-a-treatment-for-secondary-hyperparathyroidism-in-chronic-kidney-disease-to-be-presented-at-kidney-week-2015 https://www.opko.com/investors/news-events/press-releases/detail/225/opko-health-expands-portfolio-of-tests-for-inherited-forms-of-cancer https://www.opko.com/investors/news-events/press-releases/detail/224/opko-healths-genedx-business-presenting-at-national-society-of-genetic-counselors-annual-meeting https://www.opko.com/investors/news-events/press-releases/detail/223/vanderbilt-university-school-of-medicine-and-opko-health-collaborate-on-genomics https://www.opko.com/investors/news-events/press-releases/detail/222/opko-to-host-symposium-to-present-clinical-data-on-its-long-acting-human-growth-hormone-at-the-49th-annual-meeting-of-the-japanese-society-for-pediatric-endocrinology https://www.opko.com/investors/news-events/press-releases/detail/221/opko-presents-clinical-data-on-its-long-acting-human-growth-hormone-hgh-ctp-in-two-oral-presentations-at-the-54th-annual-meeting-of-the-european-society-for-pediatric-endocrinology-espe https://www.opko.com/investors/news-events/press-releases/detail/220/conversion-right-extended-on-opko-3-0-convertible-senior-notes https://www.opko.com/investors/news-events/press-releases/detail/219/opko-health-to-present-at-the-ladenburg-thalmann-2015-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/218/opko-health-announces-global-license-agreement-for-the-discovery-of-novel-antimicrobials https://www.opko.com/investors/news-events/press-releases/detail/217/opko-licensee-tesaro-receives-fda-approval-for-varubi-rolapitant https://www.opko.com/investors/news-events/press-releases/detail/216/opko-letter-to-shareholders https://www.opko.com/investors/news-events/press-releases/detail/215/opko-health-to-be-present-at-the-barrington-research-fall-investment-conference https://www.opko.com/investors/news-events/press-releases/detail/214/opko-completes-acquisition-of-bio-reference-laboratories https://www.opko.com/investors/news-events/press-releases/detail/213/opko-lab-signs-contracts-with-leading-preferred-provider-networks-for-laboratory-testing-services-including-the-4kscore-test https://www.opko.com/investors/news-events/press-releases/detail/212/opko-announces-second-quarter-operating-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/211/two-reports-on-hgh-ctp-pediatric-phase-2-clinical-data-accepted-for-oral-presentation-at-the-54th-annual-meeting-of-the-european-society-for-paediatric-endocrinology-espe-conference https://www.opko.com/investors/news-events/press-releases/detail/210/opko-to-announce-second-quarter-operating-and-financial-results-on-august-5-2015 https://www.opko.com/investors/news-events/press-releases/detail/209/fda-accepts-opkos-new-drug-application-for-rayaldee https://www.opko.com/investors/news-events/press-releases/detail/208/opko-announces-completion-of-enrollment-in-phase-3-trial-of-hgh-ctp-in-growth-hormone-deficient-adults https://www.opko.com/investors/news-events/press-releases/detail/207/opko-investee-scivac-announces-the-completion-of-transaction-with-levon-resources https://www.opko.com/investors/news-events/press-releases/detail/206/opko-and-bio-reference-laboratories-announce-early-termination-of-the-waiting-period-for-planned-acquisition https://www.opko.com/investors/news-events/press-releases/detail/205/conversion-right-extended-on-opko-3-0-convertible-senior-notes https://www.opko.com/investors/news-events/press-releases/detail/204/opko-4kscore-recommended-in-national-comprehensive-cancer-network-guidelines-for-prostate-cancer-early-detection https://www.opko.com/investors/news-events/press-releases/detail/203/opko-to-present-new-data-at-international-society-on-thrombosis-and-haemostasis-isth-2015-congress-on-its-long-acting-clotting-factor-viia https://www.opko.com/investors/news-events/press-releases/detail/202/opko-and-bio-reference-laboratories-to-hold-joint-conference-call-to-discuss-merger https://www.opko.com/investors/news-events/press-releases/detail/201/opko-announces-submission-of-rayaldee-new-drug-application-to-u-s-food-and-drug-administration https://www.opko.com/investors/news-events/press-releases/detail/200/opko-health-to-present-at-the-jefferies-2015-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/199/opko-announces-4kscore-abstracts-at-the-2015-american-urological-association-aua-annual-meeting https://www.opko.com/investors/news-events/press-releases/detail/198/opko-announces-publication-of-study-using-kallikrein-biomarkers-of-the-4kscore-test-in-a-large-community-based-referral-cohort https://www.opko.com/investors/news-events/press-releases/detail/197/opko-announces-first-quarter-operating-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/196/correcting-and-replacing-opko-to-announce-first-quarter-financial-results-on-may-11-2015 https://www.opko.com/investors/news-events/press-releases/detail/195/opko-health-acquires-eirgen-pharma https://www.opko.com/investors/news-events/press-releases/detail/194/opko-announces-publication-of-protect-study-using-kallikrein-biomarkers-in-4kscore-test https://www.opko.com/investors/news-events/press-releases/detail/193/conversion-right-triggered-on-opko-3-0-convertible-senior-notes https://www.opko.com/investors/news-events/press-releases/detail/188/phase-3-data-supporting-rayaldee-as-a-treatment-for-secondary-hyperparathyroidism-in-chronic-kidney-disease-to-be-presented-at-nkf-2015-spring-clinical-meetings https://www.opko.com/investors/news-events/press-releases/detail/192/opko-investee-scivac-ltd-enters-into-transaction-with-levon-resources https://www.opko.com/investors/news-events/press-releases/detail/189/opko-lab-receives-accreditation-from-college-of-american-pathologists https://www.opko.com/investors/news-events/press-releases/detail/191/phase-3-data-supporting-rayaldee-as-a-treatment-for-secondary-hyperparathyroidism-in-chronic-kidney-disease-to-be-presented-at-endo-2015-conference https://www.opko.com/investors/news-events/press-releases/detail/190/twelve-months-data-supporting-once-weekly-dosing-of-hgh-ctp-in-growth-hormone-deficient-pediatric-population-to-be-presented-at-endo-2015-conference https://www.opko.com/investors/news-events/press-releases/detail/185/opko-announces-fourth-quarter-operating-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/184/opko-to-announce-fourth-quarter-and-full-year-2014-financial-results-on-february-27-2015 https://www.opko.com/investors/news-events/press-releases/detail/187/opko-announces-publication-of-20-year-outcome-study-for-lethal-prostate-cancer-using-kallikrein-biomarkers-in-4kscore-test https://www.opko.com/investors/news-events/press-releases/detail/186/opko-health-to-present-at-the-2015-rbc-capital-markets-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/182/opko-submits-investigational-new-drug-application-to-initiate-a-phase-2a-trial-for-its-long-acting-coagulation-factor-viia-ctp-to-treat-hemophilia https://www.opko.com/investors/news-events/press-releases/detail/181/opko-launches-the-4kscore-test-in-mexico https://www.opko.com/investors/news-events/press-releases/detail/183/opko-claros1-analyzer-selected-for-development-of-a-rapid-lyme-disease-test-under-immuno-technologies-nih-grant https://www.opko.com/investors/news-events/press-releases/detail/180/opko-health-to-present-at-the-33rd-annual-j-p-morgan-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/179/opko-health-to-present-at-the-oppenheimer-25th-annual-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/178/opko-health-to-present-at-the-jefferies-2014-global-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/177/opko-announces-publication-of-large-prospective-multi-institutional-clinical-validation-of-the-4kscore-test-for-high-grade-prostate-cancer-in-the-united-states https://www.opko.com/investors/news-events/press-releases/detail/175/opko-to-hold-conference-call-on-november-10-2014 https://www.opko.com/investors/news-events/press-releases/detail/176/opko-announces-third-quarter-operating-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/174/neovasc-an-opko-investee-receives-fda-conditional-approval-to-initiate-tiara-i-trial-in-u-s-a-multinational-multicenter-early-feasibility-trial-of-the-tiaratm-transcatheter-mitral-valve https://www.opko.com/investors/news-events/press-releases/detail/170/opko-health-supports-national-prostate-cancer-council-legislation https://www.opko.com/investors/news-events/press-releases/detail/173/opkos-second-rayaldee-phase-3-trial-meets-primary-endpoints https://www.opko.com/investors/news-events/press-releases/detail/171/data-supporting-once-weekly-dosing-of-hgh-ctp-in-growth-hormone-deficient-pediatric-population-to-be-presented-as-a-late-breaking-presentation-at-the-european-society-of-paediatric-endocrinology-conference https://www.opko.com/investors/news-events/press-releases/detail/172/opko-licensee-tesaro-submits-new-drug-application-for-rolapitant https://www.opko.com/investors/news-events/press-releases/detail/166/opko-announces-second-quarter-operating-and-financial-results https://www.opko.com/investors/news-events/press-releases/detail/167/rayaldee-phase-3-trial-meets-primary-endpoints https://www.opko.com/investors/news-events/press-releases/detail/168/opko-submits-ind-for-rayaldee-as-adjunctive-cancer-therapy https://www.opko.com/investors/news-events/press-releases/detail/169/opko-to-announce-top-line-rayaldee-results-and-second-quarter-2014-financial-results-on-august-11-2014 https://www.opko.com/investors/news-events/press-releases/detail/165/opko-granted-patent-from-us-patent-trademark-office-for-rayaldee https://www.opko.com/investors/news-events/press-releases/detail/164/opkos-long-acting-clotting-factor-viia-ctp-receives-positive-opinion-for-three-orphan-drug-designations-in-europe https://www.opko.com/investors/news-events/press-releases/detail/162/opko-granted-patent-from-european-patent-office-for-lagova https://www.opko.com/investors/news-events/press-releases/detail/160/strong-data-from-lagova-phase-ii-clinical-study-presented-during-webcast https://www.opko.com/investors/news-events/press-releases/detail/163/opko-announces-positive-interim-six-month-lagova-hgh-ctp-phase-2-data-in-pediatric-growth-hormone-deficiency-disorder https://www.opko.com/investors/news-events/press-releases/detail/161/opko-to-hold-conference-call-to-discuss-six-month-data-from-phase-2-hgh-ctp-trial https://www.opko.com/investors/news-events/press-releases/detail/153/opko-health-to-present-at-the-jefferies-2014-global-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/151/opko-completes-acquisition-of-inspiro-medical-ltd https://www.opko.com/investors/news-events/press-releases/detail/158/data-supporting-once-weekly-dosing-of-hgh-ctp-in-growth-hormone-deficient-pediatric-population-to-be-presented-at-the-2014-iceendo-meeting https://www.opko.com/investors/news-events/press-releases/detail/159/opko-presents-4kscore-test-clinical-study-at-the-american-urological-association-plenary-session https://www.opko.com/investors/news-events/press-releases/detail/155/senesco-completes-acquisition-of-fabrus-an-opko-portfolio-company https://www.opko.com/investors/news-events/press-releases/detail/156/opko-licensee-tesaro-announces-successful-achievement-of-primary-and-all-secondary-endpoints-in-third-and-final-phase-3-trial-of-rolapitant https://www.opko.com/investors/news-events/press-releases/detail/152/opko-announces-first-quarter-operating-results https://www.opko.com/investors/news-events/press-releases/detail/154/opko-announces-dismissal-of-prolor-biotech-inc-class-action-lawsuit https://www.opko.com/investors/news-events/press-releases/detail/157/opko-creates-global-supply-chain-structure https://www.opko.com/investors/news-events/press-releases/detail/150/opko-completes-patient-enrollment-in-third-phase-3-trial-of-rayaldee https://www.opko.com/investors/news-events/press-releases/detail/147/opko-announces-presentation-of-data-on-long-acting-oxyntomodulin-at-diabetes-conference https://www.opko.com/investors/news-events/press-releases/detail/149/opko-acquires-next-generation-dry-powder-inhaler-to-treat-respiratory-disorders https://www.opko.com/investors/news-events/press-releases/detail/146/opko-health-announces-key-executive-appointments-for-renal-division https://www.opko.com/investors/news-events/press-releases/detail/148/opko-health-announces-executive-appointments https://www.opko.com/investors/news-events/press-releases/detail/145/opko-announces-launch-of-4kscore-test-for-prostate-cancer https://www.opko.com/investors/news-events/press-releases/detail/144/american-urological-association-aua-accepts-4kscore-test-clinical-study-for-plenary-presentation-at-2014-annual-meeting https://www.opko.com/investors/news-events/press-releases/detail/143/opko-announces-fourth-quarter-and-full-year-2013-results https://www.opko.com/investors/news-events/press-releases/detail/141/opkos-longer-acting-clotting-factor-viia-ctp-receives-orphan-drug-designation-in-the-u-s https://www.opko.com/investors/news-events/press-releases/detail/139/opko-announces-successful-confirmation-of-4kscore-algorithm-in-the-united-states https://www.opko.com/investors/news-events/press-releases/detail/140/opko-health-announces-the-appointment-of-greg-stanley-as-vice-president-of-sales-and-marketing-for-its-global-diagnostics-business-unit https://www.opko.com/investors/news-events/press-releases/detail/142/neovasc-an-opko-investee-reports-successful-first-human-implant-of-tiara-transcatheter-mitral-valve https://www.opko.com/investors/news-events/press-releases/detail/138/opko-health-to-present-at-the-32nd-annual-j-p-morgan-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/137/opko-health-completes-acquisition-of-laboratorio-arama-de-uruguay-limitada https://www.opko.com/investors/news-events/press-releases/detail/136/opko-records-highly-successful-exit-of-investment-in-sorrento-therapeutics https://www.opko.com/investors/news-events/press-releases/detail/135/opko-completes-patient-recruitment-in-second-phase-3-trial-of-rayaldytm https://www.opko.com/investors/news-events/press-releases/detail/133/opko-announces-investor-conference-call-details https://www.opko.com/investors/news-events/press-releases/detail/132/opko-health-to-expand-latin-american-presence-with-acquisition-of-uruguayan-pharmaceutical-company https://www.opko.com/investors/news-events/press-releases/detail/131/opko-to-hold-investor-conference https://www.opko.com/investors/news-events/press-releases/detail/134/opko-health-to-present-at-the-oppenheimer-24th-annual-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/130/opko-completes-patient-recruitment-in-first-phase-3-trial-of-rayaldytm https://www.opko.com/investors/news-events/press-releases/detail/127/opko-announces-third-quarter-2013-financial-and-operating-highlights https://www.opko.com/investors/news-events/press-releases/detail/129/neovasc-an-opko-supported-company-reports-that-reducer-achieves-primary-endpoint-in-cosira-trial-significantly-improving-function-in-patients-with-refractory-angina https://www.opko.com/investors/news-events/press-releases/detail/128/opko-commences-pivotal-clinical-validation-study-for-4kscore-as-a-predictor-of-prostate-cancer-prior-to-biopsy https://www.opko.com/investors/news-events/press-releases/detail/126/opko-obtains-final-marketing-authorization-for-citicoline-in-spain https://www.opko.com/investors/news-events/press-releases/detail/125/opko-adds-to-growing-technology-portfolio-through-strategic-investment-in-biotechnology-company-engaged-in-the-development-of-a-new-generation-of-antibodies https://www.opko.com/investors/news-events/press-releases/detail/121/conversion-right-triggered-on-opko-3-0-convertible-senior-notes https://www.opko.com/investors/news-events/press-releases/detail/120/opko-health-announces-listing-in-major-indices-on-tel-aviv-stock-exchange https://www.opko.com/investors/news-events/press-releases/detail/123/opko-health-announces-new-listing-on-tel-aviv-stock-exchange https://www.opko.com/investors/news-events/press-releases/detail/122/opko-surpasses-50-enrollment-in-second-phase-3-trial-of-rayaldy https://www.opko.com/investors/news-events/press-releases/detail/124/opko-announces-second-quarter-2013-operating-and-financial-highlights https://www.opko.com/investors/news-events/press-releases/detail/6/opkos-citicoline-products-approved-for-commercialization-in-spain https://www.opko.com/investors/news-events/press-releases/detail/5/opko-health-announces-appointment-of-david-okrongly-ph-d-as-president-of-its-diagnostics-business-unit https://www.opko.com/investors/news-events/press-releases/detail/44/opko-health-to-present-at-the-jefferies-2013-global-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/43/opko-surpasses-50-enrollment-in-first-phase-3-trial-of-rayaldytm-ctap101-capsules https://www.opko.com/investors/news-events/press-releases/detail/42/opko-announces-first-quarter-2013-operating-and-financial-highlights https://www.opko.com/investors/news-events/press-releases/detail/46/opko-health-acquires-interest-in-growing-russian-pharmaceutical-company https://www.opko.com/investors/news-events/press-releases/detail/47/opko-health-announces-publication-of-study-detecting-antibodies-in-nmo-patients-using-opko-screening-technology https://www.opko.com/investors/news-events/press-releases/detail/65/rxi-pharmaceuticals-announces-16-4-million-placement-of-common-stock https://www.opko.com/investors/news-events/press-releases/detail/64/rxi-pharmaceuticals-and-opko-health-announce-strategic-pooling-of-rnai-assets https://www.opko.com/investors/news-events/press-releases/detail/66/opko-health-completes-acquisition-of-two-phase-3-products https://www.opko.com/investors/news-events/press-releases/detail/67/opko-point-of-care-technology-demonstrated-on-mobile-device-with-cloud-connectivity-to-diagnose-and-track-disease-in-africa https://www.opko.com/investors/news-events/press-releases/detail/96/opko-health-completes-acquisition-of-brazilian-pharmaceutical-company https://www.opko.com/investors/news-events/press-releases/detail/95/clarification-regarding-exercise-and-sale-of-common-stock-options-by-opko-health-company-officer https://www.opko.com/investors/news-events/press-releases/detail/20/opko-closes-offering-of-175-million-of-3-00-convertible-senior-notes-due-2033 https://www.opko.com/investors/news-events/press-releases/detail/21/opko-prices-offering-of-175-million-of-3-00-convertible-senior-notes-due-2033 https://www.opko.com/investors/news-events/press-releases/detail/24/opko-announces-proposed-private-offering-of-150-million-convertible-senior-notes-due-2033 https://www.opko.com/investors/news-events/press-releases/detail/22/opko-health-expands-collaboration-with-bristol-myers-squibb https://www.opko.com/investors/news-events/press-releases/detail/23/opko-health-to-acquire-two-phase-3-products https://www.opko.com/investors/news-events/press-releases/detail/19/opko-health-to-present-at-the-31st-annual-j-p-morgan-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/36/opko-health-to-expand-latin-american-presence-with-acquisition-of-brazilian-pharmaceutical-company https://www.opko.com/investors/news-events/press-releases/detail/35/opko-health-completes-acquisition-of-clia-laboratory https://www.opko.com/investors/news-events/press-releases/detail/116/opko-health-announces-research-grants-from-mexican-technology-and-science-council https://www.opko.com/investors/news-events/press-releases/detail/60/opko-health-announces-launch-of-4kscore-in-europe https://www.opko.com/investors/news-events/press-releases/detail/73/opko-health-awarded-nasa-contract https://www.opko.com/investors/news-events/press-releases/detail/72/opko-health-announces-acquisition-of-growing-european-healthcare-company https://www.opko.com/investors/news-events/press-releases/detail/83/opko-health-announces-license-for-topically-active-formulation-of-ranibizumab https://www.opko.com/investors/news-events/press-releases/detail/81/opko-scientist-reports-results-at-alzheimers-association-international-conference https://www.opko.com/investors/news-events/press-releases/detail/82/opko-health-announces-appointment-of-juan-f-rodriguez-as-chief-financial-officer https://www.opko.com/investors/news-events/press-releases/detail/108/opko-health-to-acquire-stake-in-israeli-hepatitis-b-vaccine-manufacturer https://www.opko.com/investors/news-events/press-releases/detail/28/opko-health-to-present-at-the-jefferies-2012-global-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/27/opko-health-receives-core-technology-u-s-patent-allowance https://www.opko.com/investors/news-events/press-releases/detail/25/opko-health-receives-important-u-s-patent-allowance https://www.opko.com/investors/news-events/press-releases/detail/26/opko-health-enters-into-license-agreement-with-international-health-technology-for-next-generation-prostate-cancer-biomarker-panel https://www.opko.com/investors/news-events/press-releases/detail/84/opko-health-receives-important-u-s-patent-allowance https://www.opko.com/investors/news-events/press-releases/detail/85/opko-health-announces-the-start-of-phase-3-clinical-trials-of-rolapitant-for-the-prevention-of-cinv https://www.opko.com/investors/news-events/press-releases/detail/87/opko-health-acquires-chilean-pharmaceutical-company https://www.opko.com/investors/news-events/press-releases/detail/86/opko-health-announces-license-agreement-for-opkos-alzheimers-diagnostic-technology https://www.opko.com/investors/news-events/press-releases/detail/110/opko-health-expands-collaboration-with-arctic-partners https://www.opko.com/investors/news-events/press-releases/detail/109/opko-health-and-the-scripps-research-institute-announce-global-license-agreement-for-a-novel-compound-that-blocks-brain-cell-destruction-in-parkinsons-disease https://www.opko.com/investors/news-events/press-releases/detail/76/opko-invests-in-biozone-pharmaceuticals-inc https://www.opko.com/investors/news-events/press-releases/detail/74/opko-health-to-present-at-the-citi-2012-global-health-care-conference https://www.opko.com/investors/news-events/press-releases/detail/75/opko-health-inc-invests-in-chromadex-corp https://www.opko.com/investors/news-events/press-releases/detail/79/opko-health-to-acquire-chilean-pharmaceutical-company https://www.opko.com/investors/news-events/press-releases/detail/80/opko-health-acquires-next-generation-prostate-cancer-tests https://www.opko.com/investors/news-events/press-releases/detail/78/opko-health-to-present-at-the-30th-annual-j-p-morgan-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/63/opko-completes-acquisition-of-finetech-pharmaceutical-ltd https://www.opko.com/investors/news-events/press-releases/detail/62/opko-health-to-acquire-finetech-pharmaceutical-ltd https://www.opko.com/investors/news-events/press-releases/detail/61/opko-health-announces-commencement-of-u-s-clinical-trial-for-point-of-care-prostate-specific-antigen-test https://www.opko.com/investors/news-events/press-releases/detail/15/opko-health-subsidiary-receives-wall-street-journal-2011-technology-innovation-award https://www.opko.com/investors/news-events/press-releases/detail/16/opko-health-to-share-in-nih-grant-award https://www.opko.com/investors/news-events/press-releases/detail/14/opko-health-announces-acquisition-of-claros-diagnostics https://www.opko.com/investors/news-events/press-releases/detail/13/opko-completes-sale-of-ophthalmic-instrumentation-business https://www.opko.com/investors/news-events/press-releases/detail/9/opko-announces-sale-of-ophthalmic-instrumentation-business https://www.opko.com/investors/news-events/press-releases/detail/7/opko-announces-investment-by-teva-in-cocrystal-discovery-inc https://www.opko.com/investors/news-events/press-releases/detail/10/opko-health-to-transfer-listing-of-common-stock-to-the-new-york-stock-exchange https://www.opko.com/investors/news-events/press-releases/detail/8/opko-health-announces-grant-from-penn-center-for-orphan-disease-research-and-therapy https://www.opko.com/investors/news-events/press-releases/detail/37/opko-invests-in-cardiac-device-company https://www.opko.com/investors/news-events/press-releases/detail/105/opko-health-repurchases-approximately-2-4-million-shares https://www.opko.com/investors/news-events/press-releases/detail/103/opko-health-announces-research-grants-from-mexican-technology-and-science-council https://www.opko.com/investors/news-events/press-releases/detail/104/opko-health-announces-redemption-of-series-a-preferred-stock https://www.opko.com/investors/news-events/press-releases/detail/102/opko-health-to-present-at-the-jefferies-2011-global-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/41/opko-health-announces-grant-from-dravet-syndrome-foundation https://www.opko.com/investors/news-events/press-releases/detail/98/opko-health-announces-exercise-of-over-allotment-option https://www.opko.com/investors/news-events/press-releases/detail/100/opko-health-announces-completion-of-public-offering-of-common-stock https://www.opko.com/investors/news-events/press-releases/detail/97/opko-health-announces-pricing-of-public-offering-of-common-stock https://www.opko.com/investors/news-events/press-releases/detail/99/opko-health-announces-proposed-offering-of-common-stock https://www.opko.com/investors/news-events/press-releases/detail/11/opko-health-acquires-biotechnology-company-with-unique-platform-technology-to-develop-new-drugs https://www.opko.com/investors/news-events/press-releases/detail/49/opko-health-to-collaborate-with-bristol-myers-squibb-on-blood-test-for-alzheimers-disease https://www.opko.com/investors/news-events/press-releases/detail/50/opko-health-announces-publication-on-technology-underlying-blood-test-for-alzheimers-disease https://www.opko.com/investors/news-events/press-releases/detail/48/opko-health-to-present-at-the-29th-annual-j-p-morgan-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/118/opko-health-to-present-at-the-lazard-capital-markets-7th-annual-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/117/opko-announces-restatement-of-financial-statements-to-properly-account-for-series-d-convertible-preferred-stock-no-impact-on-cash-revenues-or-other-results-from-operations https://www.opko.com/investors/news-events/press-releases/detail/119/opko-invests-in-novel-antibody-biotechnology-company https://www.opko.com/investors/news-events/press-releases/detail/45/correcting-and-replacing-opko-health-to-present-at-ubs-global-life-sciences-conference https://www.opko.com/investors/news-events/press-releases/detail/29/opko-health-to-present-at-jefferies-2010-global-life-sciences-conference https://www.opko.com/investors/news-events/press-releases/detail/93/opko-health-announces-collaboration-with-mexican-research-center https://www.opko.com/investors/news-events/press-releases/detail/94/opko-health-acquires-mexican-pharmaceutical-company https://www.opko.com/investors/news-events/press-releases/detail/92/opko-health-announces-development-of-blood-test-for-alzheimers-disease https://www.opko.com/investors/news-events/press-releases/detail/89/opko-health-to-present-at-the-lazard-capital-markets-6th-annual-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/90/opko-health-completes-acquisition-of-nk-1-compounds-from-schering-corporation https://www.opko.com/investors/news-events/press-releases/detail/111/opko-health-acquires-lead-nk-1-compounds-from-schering-plough-corporation https://www.opko.com/investors/news-events/press-releases/detail/112/opko-health-acquires-chilean-pharmaceutical-company https://www.opko.com/investors/news-events/press-releases/detail/18/opko-health-announces-30-million-private-placement https://www.opko.com/investors/news-events/press-releases/detail/17/opko-health-to-present-at-ubs-2009-global-life-sciences-conference https://www.opko.com/investors/news-events/press-releases/detail/40/opko-acquires-novel-vaccine-technology-from-academia-sinica https://www.opko.com/investors/news-events/press-releases/detail/34/opko-acquires-new-platform-technology https://www.opko.com/investors/news-events/press-releases/detail/32/opko-invests-in-biotechnology-company-with-novel-approach-to-developing-new-drugs https://www.opko.com/investors/news-events/press-releases/detail/33/jamie-freedman-m-d-ph-d-joins-opko-health-as-executive-vice-president-of-rd-and-business-development https://www.opko.com/investors/news-events/press-releases/detail/30/opko-invests-in-biotechnology-company-developing-human-antibody-library https://www.opko.com/investors/news-events/press-releases/detail/31/opko-health-completes-private-placement https://www.opko.com/investors/news-events/press-releases/detail/38/opko-to-present-data-on-next-generation-anti-angiogenic-vegf165b-sparing-sirna-at-association-for-research-and-vision-in-ophthalmology-arvo-2009-meeting https://www.opko.com/investors/news-events/press-releases/detail/71/opko-receives-fda-510k-clearance-for-spectral-oct-slo-combination-imaging-system https://www.opko.com/investors/news-events/press-releases/detail/70/opko-health-initiates-clinical-trial-of-the-aquashunttm-to-treat-glaucoma https://www.opko.com/investors/news-events/press-releases/detail/101/opko-health-announces-completion-of-enrollment-for-its-phase-iii-clinical-trial-of-bevasiranib-for-treatment-of-amd https://www.opko.com/investors/news-events/press-releases/detail/91/opko-acquires-worldwide-ophthalmic-rights-to-tevas-budesonide-for-inflammatory-and-allergic-ocular-conditions https://www.opko.com/investors/news-events/press-releases/detail/68/opko-health-to-present-at-ubs-2008-global-life-sciences-conference https://www.opko.com/investors/news-events/press-releases/detail/114/opko-health-inc-set-to-join-russell-3000-index https://www.opko.com/investors/news-events/press-releases/detail/113/opko-acquires-rights-to-novel-phase-ii-agent-to-treat-viral-conjunctivitis https://www.opko.com/investors/news-events/press-releases/detail/115/newly-published-study-shows-opkos-sirna-bevasiranib-is-taken-up-by-target-tissues-in-the-eye https://www.opko.com/investors/news-events/press-releases/detail/69/opko-health-acquires-company-developing-novel-glaucoma-therapy https://www.opko.com/investors/news-events/press-releases/detail/12/opko-health-announces-issuance-of-u-s-patent-covering-the-use-and-administration-of-certain-anti-vegf-sirnas-including-its-phase-iii-compound-bevasiranib https://www.opko.com/investors/news-events/press-releases/detail/88/opko-health-and-pathogenics-announce-data-publication-demonstrating-the-potential-utility-of-nct-in-a-severe-eye-infection https://www.opko.com/investors/news-events/press-releases/detail/51/opko-health-announces-changes-to-board-of-directors https://www.opko.com/investors/news-events/press-releases/detail/52/opko-health-to-present-at-2008-wachovia-healthcare-conference https://www.opko.com/investors/news-events/press-releases/detail/53/opko-health-appoints-industry-veteran-dr-naveed-shams-as-chief-medical-officer https://www.opko.com/investors/news-events/press-releases/detail/54/opkos-bevasiranib-named-one-of-most-promising-drugs-recently-entering-phase-iii-trials https://www.opko.com/investors/news-events/press-releases/detail/55/the-frost-group-invests-20-million-in-opko-health https://www.opko.com/investors/news-events/press-releases/detail/77/opko-health-completes-acquisition-of-ophthalmic-technologies-inc https://www.opko.com/investors/news-events/press-releases/detail/59/opko-health-acquires-rights-to-innovative-ocular-product-to-prevent-serious-eye-infections https://www.opko.com/investors/news-events/press-releases/detail/57/opko-health-acquires-rights-to-clinical-stage-compound-for-dry-eye https://www.opko.com/investors/news-events/press-releases/detail/58/opko-health-appoints-pascal-j-goldschmidt-to-board-of-directors https://www.opko.com/investors/news-events/press-releases/detail/56/opko-health-to-present-at-ubs-2007-global-life-sciences-conference https://www.opko.com/investors/news-events/press-releases/detail/39/opko-health-doses-first-patient-in-phase-3-cobalt-trial-of-bevasiranib-for-the-treatment-of-amd https://www.opko.com/investors/news-events/press-releases/detail/107/opko-health-inc-announces-early-termination-of-hart-scott-rodino-waiting-period-for-proposed-purchase-of-shares-by-dr-phillip-frost https://www.opko.com/investors/news-events/press-releases/detail/106/opko-health-initiates-phase-3-trial-of-bevasiranib-for-the-treatment-of-amd https://www.opko.com/privacy-policy https://www.opko.com/investors/corporate-governance https://www.opko.com/terms-of-use https://www.opko.com/sitemap